

Dominic Pilon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5312112/publications.pdf>

Version: 2024-02-01

55
papers

760
citations

686830

13
h-index

610482

24
g-index

56
all docs

56
docs citations

56
times ranked

730
citing authors

#	ARTICLE	IF	CITATIONS
1	Economic Burden Associated With Nasal Polyposis Recurrence Among Commercially Insured Patients in the United States. <i>Otolaryngology - Head and Neck Surgery</i> , 2023, 168, 65-73.	1.1	1
2	Medication adherence among patients with advanced prostate cancer using oral therapies. <i>Future Oncology</i> , 2022, 18, 231-243.	1.1	8
3	Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2022, 40, 43-43.	0.8	3
4	Real-World Prostate-Specific Antigen Response and Treatment Adherence of Apalutamide in Patients With Non-Metastatic Castration-Resistant Prostate Cancer. <i>Urology</i> , 2022, 166, 182-188.	0.5	2
5	National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States. <i>Journal of Medical Economics</i> , 2022, 25, 792-807.	1.0	9
6	Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn's Disease Initiated on Biologic or Conventional Agents. <i>Crohn's & Colitis</i> 360, 2022, 4, .	0.5	2
7	Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder. <i>Current Medical Research and Opinion</i> , 2021, 37, 123-133.	0.9	9
8	Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer. <i>Current Medical Research and Opinion</i> , 2021, 37, 635-642.	0.9	5
9	Medication adherence among prostate cancer patients using advanced oral therapies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 44-44.	0.8	1
10	Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate. <i>Current Medical Research and Opinion</i> , 2021, 37, 675-683.	0.9	8
11	The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	1.1	151
12	Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA. <i>Pharmacoeconomics</i> , 2021, 39, 707-720.	1.7	9
13	Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 904-914.	0.5	0
14	Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries. <i>Current Medical Research and Opinion</i> , 2021, 37, 1811-1819.	0.9	15
15	Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression. <i>Advances in Therapy</i> , 2021, 38, 4900-4916.	1.3	5
16	Prostate-specific antigen response among Black and non-Black patients with advanced prostate cancer treated with apalutamide in a urology setting.. <i>Journal of Clinical Oncology</i> , 2021, 39, 124-124.	0.8	0
17	Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy. <i>Journal of Medical Economics</i> , 2021, 24, 1299-1308.	1.0	0
18	US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study. <i>Pharmacoeconomics - Open</i> , 2020, 4, 119-131.	0.9	9

#	ARTICLE	IF	CITATIONS
19	Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDESCENCE clinical trial. <i>Current Medical Research and Opinion</i> , 2020, 36, 563-570.	0.9	6
20	Are Medicaid Coverage Gaps Associated with Higher Health Care Resource Utilization and Costs in Patients with Schizophrenia?. <i>Population Health Management</i> , 2020, 23, 234-242.	0.8	3
21	Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer. <i>Advances in Therapy</i> , 2020, 37, 512-526.	1.3	17
22	Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer. <i>Advances in Therapy</i> , 2020, 37, 501-511.	1.3	14
23	Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 930.e13-930.e21.	0.8	10
24	Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 996-1007.	0.5	11
25	Long-term direct and indirect costs of ulcerative colitis in a privately-insured United States population. <i>Current Medical Research and Opinion</i> , 2020, 36, 1285-1294.	0.9	13
26	Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs. <i>Journal of Medical Economics</i> , 2020, 23, 1092-1101.	1.0	21
27	Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 176-185.	0.5	10
28	Use of home health and other healthcare delivery pathways among privately insured patients with and without treatment-resistant depression. <i>Current Medical Research and Opinion</i> , 2020, 36, 865-874.	0.9	0
29	Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis. <i>Current Medical Research and Opinion</i> , 2019, 35, 41-49.	0.9	5
30	Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis. <i>PLoS ONE</i> , 2019, 14, e0223255.	1.1	32
31	Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma. <i>Clinical Therapeutics</i> , 2019, 41, 1956-1971.	1.1	9
32	Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?. <i>Journal of Affective Disorders</i> , 2019, 255, 50-59.	2.0	12
33	Real-world impact of glycated hemoglobin reduction on treatment intensification and glycated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i). <i>Current Medical Research and Opinion</i> , 2019, 35, 1607-1614.	0.9	5
34	Medicaid spending burden among beneficiaries with treatment-resistant depression. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 381-392.	0.6	18
35	Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials. <i>Journal of Medical Economics</i> , 2019, 22, 280-287.	1.0	6
36	Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans. <i>Current Medical Research and Opinion</i> , 2019, 35, 407-416.	0.9	15

#	ARTICLE	IF	CITATIONS
37	The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. <i>Journal of Medical Economics</i> , 2019, 22, 196-203.	1.0	20
38	An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 140-147.	1.2	7
39	The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia. <i>Current Medical Research and Opinion</i> , 2019, 35, 395-405.	0.9	5
40	Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate. <i>PharmacoEconomics - Open</i> , 2019, 3, 177-188.	0.9	13
41	Long-term omalizumab outcomes in chronic idiopathic urticaria: a real-world study. <i>Allergy and Asthma Proceedings</i> , 2019, 40, 321-328.	1.0	13
42	Real-world evaluation of HbA1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida. <i>Current Medical Research and Opinion</i> , 2018, 34, 1099-1115.	0.9	4
43	Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics. <i>Current Medical Research and Opinion</i> , 2018, 34, 1377-1388.	0.9	6
44	Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States. <i>Dermatology and Therapy</i> , 2018, 8, 69-83.	1.4	5
45	Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting. <i>Current Medical Research and Opinion</i> , 2018, 34, 1125-1133.	0.9	8
46	Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics. <i>Journal of Medical Economics</i> , 2018, 21, 135-143.	1.0	13
47	Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma. <i>Allergy and Asthma Proceedings</i> , 2018, 39, 127-135.	1.0	12
48	Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab. <i>Allergy and Rhinology</i> , 2018, 9, 215265671876338.	0.7	1
49	Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: A real-world study in the United States. <i>Allergy and Asthma Proceedings</i> , 2018, 39, 201-211.	1.0	12
50	Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States. <i>Allergy and Asthma Proceedings</i> , 2018, 39, 191-200.	1.0	12
51	Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 24-32.	1.1	97
52	Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors. <i>BMC Endocrine Disorders</i> , 2017, 17, 32.	0.9	4
53	Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. <i>BMC Psychiatry</i> , 2017, 17, 207.	1.1	37
54	Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 619-629.	0.8	33

#	ARTICLE	IF	CITATIONS
55	A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy. International Journal of COPD, 2017, Volume 12, 1825-1836.	0.9	13